68Ga-OPS202 Study for Diagnostic Imaging of GEP NET

Inclusion Criteria: * A diagnostic CT or MRI of the tumor region within the previous 6 months prior to dosing day is available. * A somatostatin receptor scan with results in the previous 6 months prior to dosing day. * At least 1 lesion detected by the previous somatostatin receptor scan. * Not exceeding 30 lesions / organ detected by the previous somatostatin receptor scan. * Blood test results as follows (WBC: ≥ 3\*109/L, Hemoglobin: ≥ 8.0 g/dL, Platelets: ≥ 50x109/L, ALT, AST, AP: ≤ 5 times ULN, Bilirubin: ≤ 3 times ULN) * ECG: any abnormalities have to be clarified by a cardiologist. * Serum creatinine: within normal limits or \< 120 μmol/L for patients aged 60 years or older. * Calculated GFR ≥ 45 mL/min. * Negative pregnancy test in women capable of child-bearing. Exclusion Criteria: * Known hypersensitivity to 68Ga, to NODAGA, to JR11 or to any of the excipients of 68Ga-OPS202. * History of, or current active allergic or autoimmune disease, including asthma or any condition requiring long-term use of corticosteroids. * Presence of active infection at screening or history of serious infection within the previous 6 weeks. * Known human immunodeficiency virus (HIV) or positive serology for HIV, hepatitis B and C. * Any condition that precludes raised arms position for prolonged imaging purposes. * Neuroendocrine tumor specific treatment between last somatostatin receptor imaging and start of this study. Exception is the therapeutic use of any somatostatin analog (see …